Abstract: Extrasynaptic d subunit-containing c-aminobutyric acid type A receptors (d-GABA A Rs) are emerging as targets for a number of neuropsychopharmacological drugs, including the direct GABA site agonist gaboxadol and neuroactive steroids. Among other regions, these d-GABA A Rs are functionally expressed in the ventral tegmental area (VTA), the cell body region of mesocorticolimbic dopamine (DA) system important for motivated behaviours, and in the target region, the nucleus accumbens. Gaboxadol and neurosteroids induce VTA DA neuron plasticity ex vivo, by inhibiting the VTA GABA neurons, and aversive place conditioning, which are absent in the d-GABA A R knockout mice (d-KO). It is not known whether d-GABA A Rs are important for the effects of other drugs, such as opioids (that also inhibit GABA neurons) and stimulants (that primarily elevate monoamine levels). Here, we used d-KO mice and conditioned place preference (CPP) test to study the rewarding effects of morphine (20 mg/kg), methamphetamine (1 mg/kg) and mephedrone (5 mg/kg). Morphine-induced nociception was also assessed using tail-flick and hot-plate tests. We found that the d-KO mice failed to express morphine-induced CPP, but that they were more sensitive to morphine-induced analgesia in the tail-flick test. In contrast, stimulant-induced CPP in the d-KO mice was similar to that in the wild-type controls. Thus, the conditioned rewarding effect by opioids, but not that of stimulants, was impaired in the absence of d-GABA A Rs. Further studies are warranted to assess the potential of d-GABA A R antagonists as possible targets for reducing morphine reward and potentiating morphine analgesia.
Ligand-gated ionotropic c-aminobutyric acid type A receptors (GABA A Rs) are pentamers composed of selected combinations from 19 gene products that are widely expressed throughout the mammalian brain [1] . These receptors also participate in the regulation of the activities of the reward-and motivation-related neuronal circuits [2] . In the ventral tegmental area (VTA), both inhibitory GABAergic neurons and mesocorticolimbic dopaminergic neurons (VTA DA neurons) express GABA A receptors [3, 4] . Depending on which location these receptors are activated, they may promote rewarding or aversive motivation by regulating VTA DA neurons and/or by exerting their effects on DA neuron projections and target neurons, for example, in the nucleus accumbens of the ventral striatum or the medial prefrontal cortex [5] [6] [7] .
There are two main types of GABA A receptors, the synaptic c2 subunit-containing GABA A Rs, which mediate phasic inhibition, and the extrasynaptic d subunit-containing GABA A Rs, which mediate tonic inhibition when combined in pentameric receptor channels together with a6, a4 and/or a1 subunits [8, 9] . These receptor populations differ in subunit composition and kinetic properties. The synaptic receptors typically have high conductance, quick desensitization and low GABA sensitivity, whereas the extrasynaptic receptors have low conductance, slow desensitization and high sensitivity to ambient GABA. Moreover, the pharmacology is different in these two types of GABA A Rs, with the synaptic receptors being allosterically facilitated by benzodiazepines and the extrasynaptic receptors showing preference to GABA site agonist gaboxadol (THIP) and neurosteroid agonists [10] . The actions of the latter compounds are strongly diminished in the GABA A R d-subunit knockout (d-KO) mice [11, 12] . Presently, there are no selective antagonists to these types of GABA A receptors.
Addictive and rewarding drugs of abuse with different primary mechanisms of action all induce prolonged glutamate receptor neuroplasticity in the VTA DA neurons [2, 13] . For example, after a single dose in vivo, opioids that are known to depress GABA release from VTA GABA neurons induce similar VTA DA neuron plasticity as stimulant amphetamines and cocaine that primarily act by inhibiting dopamine transporters. This neuroplasticity effect has been suggested to constitute an early event in the cascade of effects of addictive drugs [14, 15] . Interestingly, the preferential d-GABA A R agonists gaboxadol and ganaxolone (a neurosteroid agonist) induce similar VTA DA neuroplasticity as the drugs of abuse [4, 16] . However, if anything, these drugs produce aversion in place conditioning, which was abolished in the d-KO mice. Ganaxolone was shown to increase tonic GABA currents in the VTA GABA neurons, but not in VTA DA neurons [4] , suggesting a disinhibitory mechanism of action in a manner dependent on the d-GABA A Rs.
Opioids are rewarding and self-administered when injected into the VTA [17] . In the present study, we wanted to test whether morphine-induced place conditioning, a model of drug-induced neuroadaptation, is deficient in the d-KO mice. Opioids are known to depress GABA release onto VTA DA neurons via pre-synaptic l-opioid receptors [18, 19] long-term depression of VTA GABA synapses [20] and reduce tonic GABA conductance in specific neurons in the brainstem in d-GABA A R-dependent manner [21] . Therefore, this study should reveal whether the d-GABA A Rs play a role in the rewarding actions of opioids. As we found impaired reward in the d-KO mice, we tested whether there is a general difference in opioid sensitivity between the mouse lines by measuring nociceptive sensitivity to cumulative doses of morphine in tail-flick and hot-plate tests. As stimulants are not known to affect these inhibitory mechanisms and are not rewarding, self-administered or inducing locomotor hyperactivity when injected into the VTA [17, 22, 23] , we also tested whether two stimulants, classical methamphetamine (METH) and a related designer drug b-keto-amphetamine mephedrone (4-methylmethcathinone, 4MMC) [24] , can induce conditioned place preference (CPP) in the d-KO mice. Furthermore, as ethanol (EtOH) has been shown to enhance the actions of stimulants, including 4MMC [25, 26] , we tested whether the combination of 4MMC and EtOH produces a different CPP than 4MMC or ethanol alone in these mouse lines.
Materials and Methods
Animals. Adult GABA A R d-KO mice (8-11 weeks old) [11] and their wild-type littermates (d-WT) were used for behavioural studies. Male mice were used in morphine and METH/4MMC experiments, while for the 4MMC + EtOH experiment, we used 60 male and 22 female mice. The same-sex mice were housed two to six per cage with free access to standard diet and water. All drug injections (s.c. or i.p.) and behavioural tests were performed between 7:00 a.m. and 08:00 p.m. with lights on. All animal work was conducted according to relevant national and international guidelines. Animal experiments were authorized by the National Animal Experiment Board in Finland (El€ ainkoelautakunta, ELLA).
Spontaneous locomotor activity. Locomotor activity was analysed using the video-tracking software Ethovision XT (Version 10.1, Noldus Information Technology, Wageningen, the Netherlands) in 19 3 36 cm cages [16] . The mice received drugs or saline vehicle and were then immediately transferred into the locomotor activity cages. Explorative distances travelled during the total experimental period and successive 5-min. intervals were calculated and compared between the treatments.
Conditioned place preference test. We studied the rewarding effects of morphine, METH and 4MMC by an unbiased paradigm of conditioned place preference (CPP) test, while the effects of 4MMC and EtOH were studied with a biased version of the CPP test. A change of the CPP paradigms was due to changes in animal facility and conditions of the experimental room.
The unbiased CPP protocol contained three phases, habituation, conditioning and post-conditioning phases [4] . Firstly, a 30-min. habituation session was performed to acclimate the mice to the conditioned place preference apparatus by injecting saline (10 ml/kg, i.p.) and placing the animals in the conditioning cages without the conditioning floor materials. On the next day, the conditioning phases began containing one daily 30-min. session. On alternate days, mice were injected with either saline vehicle or morphine/stimulant (the order of the injections was counterbalanced over the groups, different batches of na€ ıve mice being used in morphine and stimulant experiments) and were immediately placed either on a metal or plastic floor mat depending on their group. We used a metal floor mat with perforated holes (⌀ 1 cm) and a plastic floor mat with deep horizontal dents. The cages were cleaned after every session with water. The groups were divided so that metal+ subgroup received a drug (morphine 20 mg/kg, METH 1 mg/kg or 4MMC 5 mg/kg) in contingency with the metal floor mat, while the metal-subgroup received the drug in contingency with the plastic floor mat. The conditioning sessions were performed for eight sessions. The post-conditioning place preference test sessions took place 24 hr after the last conditioning session. In the 30-min. post-conditioning test session, bisected floor mats were used and time spent on both floor mats was recorded by Ethovision and compared against each other. The results are presented as the time spent on the metal floor: CPP was evidenced by long time on metal+ and short time on metalÀ, as reviewed in detail by Cunningham et al. [27] .
A biased CPP protocol contained three separate phases [28] . In a pre-conditioning phase, initial preferences to floor mat types were recorded, and each mouse was calculated a preferred floor mat. The floor mats were placed so that they bisected the cages. Of the three 15-min. pre-conditioning sessions on succeeding days, data from the last one were used to calculate the initial preference. The conditioning phase contained two 30-min. sessions daily, one in the morning (07:00 a.m.-11:00 a.m.) and the other in the evening (04:00 p.m.-08:00 p.m.). In the morning sessions, all mice were injected (i.p.) with saline vehicle, and immediately after the injection, mice were placed in the cages with the preferred floor mat. In the evening sessions, mice were injected according to their group with vehicle, 4MMC (5 mg/kg), EtOH (1 g/kg) or 4MMC (5 mg/kg) + EtOH (1 g/ kg) -combination and immediately placed to cages with the less preferred floors. The conditioning phase was performed for 4 days. The post-conditioning phase took place after 72 hr from the last conditioning day. In the 30-min. post-conditioning test sessions, the same bisected floor mats were used as in the pre-conditioning phase. A difference in time ('time shift') a mouse spent on the less preferred floor mat during pre-conditioning and post-conditioning tests was calculated as the measure of CPP. Four independent batches of mice with all groups were tested and the results pooled.
Nociception tests. Nociceptive responses in morphine-na€ ıve mice were tested by using the tail-flick and hot-plate tests. The tail-flick test was used for the evaluation of predominantly spinal responses, whereas the hot-plate test was used for the evaluation of predominantly supraspinal responses [29] . For these tests, cumulative morphine (2 mg/kg/dose s.c., ad 8 mg/kg,) was administered 15 min. before the measurement of nociceptive responses, after which the next dose was given. After each morphine dose, the tail-flick test was performed first, followed immediately by the hot-plate test.
In the tail-flick test, a mouse was held in place, and a lamp under its tail was turned on (Tail Flick 37360; Ugo Basile, Gemonio, Italy) [29] . Time was taken until the mouse lifted/flicked its tail. The time was then compared to maximal possible effect (%MPE), which was calculated using the following formula with a cut-off latency of 10 sec.:
In the hot-plate test, a mouse was placed on a floor plate that had a stable temperature set at 52°C (Hot/Cold Plate 35100, Ugo Basile) [29] and latency until the mouse started lifting up its feet was recorded. Immediately thereafter, the mouse was removed from the plate. The longer the latency, the larger the reduction was in nociception. To prevent tissue damage, a cut-off time of 60 sec. was imposed.
Drugs. All drugs were administered at a volume of 10 ml/kg bodyweight. Morphine concentrations are given as free base per unit of volume. Morphine hydrochloride (University Pharmacy, Helsinki, Finland), METH hydrochloride (Sigma-Aldrich, St. Louis, MO, USA) and ethanol (Altia Oyj, Rajam€ aki, Finland) were dissolved in 0.9% saline (Sal) for i.p. or s.c. injections.
Racemic mephedrone (4MMC) was also dissolved in 14% (by vol) ethanol/Sal solution immediately before i.p. administration. One batch of 4MMC was acquired from the Department of Forensic Medicine, Faculty of Medicine, University of Helsinki. The compound was analysed for purity by gas chromatography and Fourier transform infrared spectroscopy and found to be pure (>95%) hydrochloride salt [30] . An additional batch of 4MMC hydrochloride was synthesized under the permission by the Finnish Medicines Agency Fimea (3/2015, 3.7.2015, Helsinki, Finland), using the synthesis protocols that are described in the Supporting information.
Statistical analyses. Results are presented as means AE S.E.M. Data were tested with the IBM SPSS Statistics 24 software (IBM, Armonk, New York, NY, USA) and Prism 5 (GraphPad Software, La Jolla, CA, USA) using uni-or multivariate ANOVA followed by a Bonferroni t-test, or Student's t-test when comparing two groups.
Results
Opioid effects. Morphine-induced CPP was observed in the d-WT mice (p < 0.05), but failed in the d-KO mice (p = 0.245), as only the d-WT mice preferred the floor mat on which they were conditioned ( fig. 1A) . There was no difference between the genotypes in locomotor activity after vehicle (fig. 1B,C) . When we divided the total movements into 5-min. bins, we found that there was a notable increase in locomotion in the second bin (p = 0.002; Bonferroni t-test; fig. 1B ), without a significant genotype effect (interval 9 genotype F 5,250 = 0.2, p = 0.96). Both genotypes showed locomotor sensitization over drug conditioning sessions (session F 3,150 = 34.9, p < 0.001; session 9 genotype F 3,150 = 0.8, p = 0.48; fig. 1C ).
We then tested whether the failure in the development of CPP in the d-KO mice is associated with changes in the morphine sensitivity of nociception using two tests, one preferentially testing spinal reflex responses (tail-flick) and the other supraspinal mechanisms (hot-plate) [29] . We found that the tail-flick test showed morphine-induced dose-dependent analgesia ( fig. 1D ; dose F 4,125 = 89.0, p < 0.0001). The d-KO mice showed higher sensitivity to 4 and 6 mg/kg doses of morphine than their wild-type littermates (genotype 9 dose F 4,125 = 3.0, p = 0.02). Like in the tail-flick test, a dosedependent decrease in nociception was shown in both genotypes in the hot-plate test ( fig. 1E ; dose F 5,150 = 24.9, p < 0.0001), but there was no difference between the genotypes (genotype F 1,150 = 0.2, p = 0.7).
Psychostimulant effects.
In the first experiment with psychostimulants, we compared methamphetamine (METH) and mephedrone (4MMC) at the relative dose levels (1:5), which reflect their equivalent efficacies in blocking the dopamine transporter and dose levels in human abuse [30] . We found that METH induced CPP (floor association) in both wild-type and d-KO mice ( fig. 2A ; p < 0.04 Student's t-test), while 4MMC induced a significant CPP in the d-KO mice ( fig. 2D , p < 0.001) and tended to do it also in the d-WT mice (p = 0.061). Anyway, this result contrasted the effect that we found with morphine, as both stimulants were effective in d-KO mice, whereas morphine was not. Both drugs increased locomotion, although only 4MMC was clearly effective on the first day of administration at the dose levels used ( fig. 2B, E) . Interestingly, during the first session there was a significant time interval 9 treatment 9 genotype Fig. 2 . Place conditioning with methamphetamine (1 mg/kg; METH) and mephedrone (5 mg/kg; 4MMC) in wild-type and d-KO mice. The metal+ subgroup received a drug in contingency with the metal floor mat, while the metalÀ subgroup received the drug in contingency with the plastic floor mat. Saline control data were combined within the genotypes (session 9 genotype 9 treatment F 3,111 = 2.189, p = 0.093). Mice were conditioned either to a metal or plastic floor mat with saline or drug. (A) Time on metal floors during testing for expression of CPP in the METH-conditioned mice increased in both genotypes (for d-WT, n = 6 and 4 for metal+ and metalÀ conditioned mice, respectively; for d-KO, n = 12 and 16 for metal+ and metalÀ conditioned mice, respectively). **p < 0.01, ***p < 0.001 (Student's t-test). (B) Locomotor activities in the first conditioning session after saline and METH injections, showing no clear drug effects or differences between the genotypes. (C) Total movements are shown for each conditioning session after saline and METH injections. Both genotypes showed sensitization to METH, as indicated by increased distances moved in later two sessions as compared to the first one. . 2E) . Interestingly, during repeated conditioning sessions, METH induced locomotor sensitization, while 4MMC did not ( fig. 2C, F) , which was indicated by session 9 treatment 9 genotype interaction (F 3,168 = 5.98, p = 0.001) for METH, but not for 4MMC (F 3,189 = 1.05, p = 0.37).
As alcohol has been shown to modify stimulant actions [25, 26, 31] , we wanted to see whether a low dose of ethanol (1 g/kg) would affect the rewarding effect of 4MMC (5 mg/ kg). In this experiment, 4MMC induced CPP similarly in d-WT and d-KO mice as the time shifts differed notably after conditioning sessions between 4MMC and saline (p < 0.01) and 4MMC + EtOH (p < 0.05) (treatment F 3,74 = 5.2, p = 0.003; no genotype effect F 1,74 = 1.1, p = 0.29) (fig. 3A) . However, the combination of 4MMC + EtOH did not differ from 4MMC alone nor from the saline controls (p > 0.05). EtOH or vehicle failed to produce CPP. Our findings indicate that the genotypes did not differ from each other in their rewarding effects to repeated 4MMC conditionings and that a low dose of ethanol hardly affected the effect of 4MMC.
The genotypes did not differ in basal locomotor activity in saline sessions (not shown; session 9 genotype F 3,222 = 0.5, p = 0.7). During the drug conditioning sessions, there was no difference between the genotypes ( fig. 3C ; session 9 genotype F 3,198 = 0.9, p = 0.5). Total locomotion divided into 5-min. intervals during the first conditioning session ( fig. 3B ) did not reveal any clear differences between the genotypes (interval 9 genotype F 5,330 = 0.3, p = 0.96). The overall decrease in locomotion (habituation) during the 30-min. session was detected in both genotypes in all treatment groups (interval 9 treatment F 15,330 = 8.2, p < 0.001). Both genotypes showed hyperlocomotion after drug treatments on all conditioning sessions with a minor sensitization effect (session 9 treatment F 9,198 = 2.25, p < 0.02), as the drug conditioning sessions 2 and 4 showed higher locomotion than the first session ( fig. 3C ). Expression of CPP after repeated administrations of saline vehicle (Sal; 10 ml/kg, 0.9% saline; n for d-WT and d-KO mice 5 and 9, respectively), 4MMC (5 mg/kg; n = 15 and 8 for d-WT and d-KO mice, respectively), ethanol (EtOH, 1 g/kg; n = 10 and 12 for d-WT and d-KO mice, respectively) and 4MMC + EtOH (5 mg/kg + 1 g/kg; n = 14 and 12 for d-WT and d-KO mice, respectively) was calculated by subtracting the time a mouse spent on an initially less preferred floor mat on the final test session from the time the mouse spent on it in the pre-test session (time shift). Higher positive time shifts mean stronger CPP. *p < 0.05, **p < 0.01 for the significance of the difference from 4MMC-conditioned mice (Bonferroni t-test). (B) Locomotor activities after injections. Here, the 30-min conditioning session is divided in 5-min. intervals, showing clear habituation of the activity for all treatment groups, the activity being initially higher than at the end. (C) Total locomotion during the four 30-min. sessions is shown for each treatment. While there is a significant session 9 treatment interaction, but no session 9 genotype interaction, individual group differences could not be tested:
# p < 0.05, ### p < 0.001 for the significance of the difference between the first-day sessions and later sessions (session F 3,198 = 10.797, p < 0.001).
Genders (n = 60 males and 22 females) were combined within the genotypes, as there were no gender interactions in CPP (gender 9 treatment F 1,66 = 1.757, p = 0.190) nor in locomotion (session 9 gender 9 treatment F 9,174 = 1.160, p = 0.323).
Discussion
We found here that GABA A R d-KO mice fail to express conditioned reward (CPP) after place conditioning with morphine at the dose that induced hyperlocomotion and locomotor sensitization similar to that found in the wild-type mice. It has been well-established that DA release from the VTA DA neurons in the target region, the nucleus accumbens (NAc) is crucial for opioid reward, but rewarding effects of opioids can be provoked by both intra-VTA and intra-NAc administrations at the rostral sites of the NAc shell [32] . This reward is directly correlated with the amount of dopamine that is released. Opioids activate pre-synaptic l-opioid receptors to inhibit GABA release in the VTA [18, 19] , which disinhibits the VTA DA neurons. Amphetamine-type psychostimulants are known to induce their rewarding effect when administered into the NAc, but not when injected into the VTA [17, 22] , by an inhibitory action on transporters of dopamine and other monoamines [33, 34] . Importantly, we show here that two psychostimulants, METH and 4MMC, induced rewarding effects in both GABA A R d-WT and d-KO mice, indicating that both genotypes have the capacity to express drug-induced reward.
We may suggest that the failure of the GABA A R d-KO mice to create morphine-induced CPP is due to the lack of tonic GABA A R-mediated inhibition in many brain regions [35] [36] [37] [38] [39] , including the VTA, where tonic GABA A R-mediated inhibition is functional in the wild-type GABA neurons rather than DA neurons [4] . In the VTA, opioid-induced reduction in GABA release [18, 19] should also reduce the tonic inhibition of these same neurons as ambient GABA concentrations decrease, which should actually counteract the disinhibition in the d-WT mice, but not in the d-KO mice. Indeed, in the neurons of gastric motor medial nucleus of the tractus solitarius, l-opioids reduce tonic GABA A R-mediated current without altering the synaptic GABA A R-mediated currents [21] . Thus, it is unlikely that the altered effects of morphine on the VTA alone would abolish its rewarding effects in the d-KO mice. Other brain regions might well be involved.
There are known compensations in the d-KO mice due to global deficiency of d-GABA A R subunits: the c2 subunit levels are increased [40, 41] , which results into increased synaptic GABA A R-mediated inhibition [21, 42] . Although not shown for the d-KO mice, it is possible that the deficiency of the tonic conductance is compensated by increased K + -leak currents, similar to the increased TASK-1 currents in cerebellar granule neurons of the a6-GABA A R subunit knockout mice (also deficient in cerebellar d-GABA A R subunits) [43, 44] . These compensations might have contributed to the increased spinal analgesic response to morphine in the d-KO mice ( fig. 1C) .
d-GABA A Rs play an important role in stress reactions, with the d-KO mice having blunted responses [45] and chronic stress reducing the expression of d-GABA A Rs [46] . Normally hypothalamic-pituitary-adrenal axis is activated by corticotrophin-releasing hormone neurons, which are, on the other hand, under the control of tonic GABAergic inhibition. In stress, this tonic inhibition is reduced, which effect is impaired in the d-KO mice [45] . Glucocorticoids that are increased in stressful conditions can also be reinforcing [47] . Rats reacting to novelty with high locomotion, exploration, and corticosterone levels, are also especially prone to stimulant addiction [48] . In the present study, the d-KO mice showed normal rewarding effects to METH and 4MMC (figs 2 and 3) . Although stimulants may also have a delayed effect on VTA GABA neurons by activating an inhibitory feedback pathway from the ventral striatum [49] , our results are consistent with the idea that both METH and 4MMC produce a rapid DA release in the NAc associated with a specific environment that will then be memorized. Blunted stress responses appear not to be able to prevent the conditioning to stimulants.
The stimulants may enhance cognition by increasing vigilance, attention and response speed [50] , while opioids may depress cognitive functions [51] . Although opioids generally inhibit hippocampal neurogenesis and cognition [52] , in wildtype rodents, morphine-induced CPP is associated with increased ventral hippocampal neurogenesis and expression of BDNF and TrkB mRNAs [53] . While the d-KO mice do not have drastic alterations in general learning and memory [11] , they do have deficits in hippocampal learning and memory, neurogenesis and inhibitory functions [54] [55] [56] . Thus, it is plausible that place conditioning with morphine failed in these mice because of learning/memory impairment potentiated by the combination of morphine administration and deficiency of extrasynaptic d-GABA A Rs.
Although ethanol is known to enhance the effects of psychostimulants in rodents [31, 57] , including 4MMC [25, 26] , we failed to enhance the 4MMC effects (reward and locomotion) with a low dose of ethanol ( fig. 3 ). This failure was most likely due to a lower dose of 4MMC that we used (5 versus 25 mg/kg). Our result was independent of the d-GABA A Rs, although low concentrations of ethanol have been claimed in some studies to specifically facilitate the functions of the d-GABA A Rs ( [58] , but see [59, 60] ). However, with 3,4-methylenedioxy-methamphetamine (MDMA), ethanol potentiation is pharmacokinetic, leading to increased brain MDMA levels [61] , which would be independent of the actions of ethanol on the nervous system.
Pharmacological activation of extrasynaptic d-GABA A Rs by gaboxadol and muscimol has been shown to reduce acute morphine-induced hyperactivity and sensitization [62, 63] , which were similar here between the d-WT and d-KO mice ( fig. 1) , suggesting that these receptors do not regulate these morphine effects, but that their activation by agonists may shut down neuronal mechanisms mediating the processes. Single doses of both gaboxadol and the benzodiazepine diazepam persistently alter glutamate synapses of VTA DA neurons [16, 64] , but this neuroplasticity is not associated with altered locomotion [65] .
In wild-type mice, systemic or intra-NAc injection of gaboxadol blunt cocaine-induced CPP, but not hyperactivity [38] , while no drug effects are detectable in a4-GABA A R KO mice (which are also deficient in forebrain d subunits and related extrasynaptic inhibition). In summary, extrasynaptic d-GABA A Rs may modify different behavioural responses to morphine and stimulants. However, there is no specific antagonist for the d-GABA A Rs [66] , which could be used to directly test their pharmacological roles.
Our results suggest that antagonism of d-GABA A Rs might constitute a novel treatment option for opioid abuse and addiction, but not for stimulant addiction. Interestingly, antagonism of these extrasynaptic receptors has been found to facilitate the long-term rehabilitation from acute stroke in mouse models [67] , which together with the present results warrants efforts in developing rapid-acting selective antagonists for the extrasynaptically localized d-GABA A Rs that mediate tonic inhibition in the brain.
